Premium
High doses and low doses of α 2 ‐interferon plus Zidovudine in the management of Kaposi's sarcoma associated with human immunodeficiency virus infection
Author(s) -
Hernåndez Dimas E.
Publication year - 1993
Publication title -
journal of the european academy of dermatology and venereology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.655
H-Index - 107
eISSN - 1468-3083
pISSN - 0926-9959
DOI - 10.1111/j.1468-3083.1993.tb00023.x
Subject(s) - medicine , zidovudine , sarcoma , kaposi's sarcoma , human immunodeficiency virus (hiv) , interferon , gastroenterology , viral disease , virology , pathology , human herpesvirus
Background α‐2‐lnterferon (α 2 ‐IFN) is recommended as an effective agent for the treatment of epidemic Kaposi's sarcoma (EKS). Objective Trial of efficacy of low dose α 2 ,‐IFN plus Zidovudine (AZT) for the treatment of EKS. Study design Non‐randomised study. Subjects Ten homosexual or bi‐sexual male patients with cutaneous lesions of Kaposi's Sarcoma, divided into two equal groups. Intervention High dose α 2 ‐IFN (10‐30 million units/three times per week) alone, or combination of low dose α 2 ‐IFN (5 million units three times per week) with AZT (500 mg/day). Results High dose , IFN: 3 stable disease and 2 disease progression. Low dose , IFN plus AZT: 1 complete remission, 2 partial remissions and 2 stable disease. Outcome Preliminary results suggest the usefulness of low dose α 2 ‐IFN plus AZT in the treatment of cutaneous lesions of EKS without visceral involvement.